[8-K] Q32 Bio Inc. Reports Material Event

Rhea-AI Filing Summary

Q32 Bio Inc. (QTTB) announced it has completed enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart for alopecia areata. The company disclosed the update via a press release titled “Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata,” furnished as Exhibit 99.1.

false 0001661998 0001661998 2025-10-21 2025-10-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 21, 2025

Q32 Bio Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-38433		47-3468154
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

830 Winter Street
Waltham, Massachusetts		02451
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 781 999-0232

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		QTTB		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On October 21, 2025, Q32 Bio Inc. issued a press release titled “Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1		Press Release issued by Q32 Bio Inc. on October 21, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Q32 BIO INC.
Date: October 21, 2025				By:		/s/ Jodie Morrison
				Name: Title:		Jodie Morrison Chief Executive Officer

FAQ

What did QTTB announce in its 8-K?

The company reported completion of enrollment in Part B of the SIGNAL-AA Phase 2a trial of bempikibart for alopecia areata, via a press release.

Which program is referenced by Q32 Bio (QTTB)?

The SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata.

What exhibit contains the press release for QTTB?

Exhibit 99.1 includes the press release detailing the enrollment completion.

When was the press release issued by Q32 Bio (QTTB)?

October 21, 2025.

What is Q32 Bio’s trading symbol and exchange?

Its common stock trades on The Nasdaq Global Market under the symbol QTTB.

What is the form type for this QTTB filing?

Form 8-K.